INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULAR MEMBRANE DUE TO ANGIOID STREAKS
PURPOSE: To investigate the results of intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to angioid streaks and to assess the factors influencing disease progression.
METHODS: Patients treated with intravitreal bevacizumab (1.25 mg/0.05 mL) for CNV secondary to angioid streaks were reviewed retrospectively. In addition to demographic findings, ophthalmologic findings at baseline and during follow-ups were recorded.
RESULTS: Twenty-three eyes of 20 patients (mean age, 45.7 years; 7 women) were included in the study. Mean follow-up was 23 months. Mean number of injections was 5.1. Initial and final logMAR visual acuity was not different (0.53 ± 0.33 and 0.60 ± 0.40 logMAR, P = 0.79). At the last examination, patients with final active CNV (N = 14) were younger (mean age, 42 years) than patients with final inactive CNV (N = 9) (mean age, 52 years). The former group required higher number of injections (6.6 vs. 2.8, P = 0.013). Eyes with pseudoxanthoma elasticum (N = 10) needed injections every 4.4 months while the others (N = 13) every 7.2 months (P = 0.072). Pseudoxanthoma elasticum positivity ended up with active membranes in 70% of the cases, composing half of the overall final active CNVs in this study.
CONCLUSION: Intravitreal bevacizumab stabilized vision in eyes with CNV and angioid streaks. At younger ages, CNV behaved more aggressively and seemed to be more resistant to treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Retina (Philadelphia, Pa.) - 35(2015), 10 vom: 01. Okt., Seite 2001-10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alagöz, Cengiz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2S9ZZM9Q9V |
|---|
| Anmerkungen: |
Date Completed 12.05.2016 Date Revised 24.09.2015 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/IAE.0000000000000605 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM249227142 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM249227142 | ||
| 003 | DE-627 | ||
| 005 | 20231224153120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/IAE.0000000000000605 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0830.xml |
| 035 | |a (DE-627)NLM249227142 | ||
| 035 | |a (NLM)25996427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alagöz, Cengiz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULAR MEMBRANE DUE TO ANGIOID STREAKS |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2016 | ||
| 500 | |a Date Revised 24.09.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: To investigate the results of intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to angioid streaks and to assess the factors influencing disease progression | ||
| 520 | |a METHODS: Patients treated with intravitreal bevacizumab (1.25 mg/0.05 mL) for CNV secondary to angioid streaks were reviewed retrospectively. In addition to demographic findings, ophthalmologic findings at baseline and during follow-ups were recorded | ||
| 520 | |a RESULTS: Twenty-three eyes of 20 patients (mean age, 45.7 years; 7 women) were included in the study. Mean follow-up was 23 months. Mean number of injections was 5.1. Initial and final logMAR visual acuity was not different (0.53 ± 0.33 and 0.60 ± 0.40 logMAR, P = 0.79). At the last examination, patients with final active CNV (N = 14) were younger (mean age, 42 years) than patients with final inactive CNV (N = 9) (mean age, 52 years). The former group required higher number of injections (6.6 vs. 2.8, P = 0.013). Eyes with pseudoxanthoma elasticum (N = 10) needed injections every 4.4 months while the others (N = 13) every 7.2 months (P = 0.072). Pseudoxanthoma elasticum positivity ended up with active membranes in 70% of the cases, composing half of the overall final active CNVs in this study | ||
| 520 | |a CONCLUSION: Intravitreal bevacizumab stabilized vision in eyes with CNV and angioid streaks. At younger ages, CNV behaved more aggressively and seemed to be more resistant to treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a VEGFA protein, human |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 700 | 1 | |a Alagöz, Neşe |e verfasserin |4 aut | |
| 700 | 1 | |a Özkaya, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Çelik, Uğur |e verfasserin |4 aut | |
| 700 | 1 | |a Turan, Miray F |e verfasserin |4 aut | |
| 700 | 1 | |a Yazici, Ahmet T |e verfasserin |4 aut | |
| 700 | 1 | |a Çekiç, Osman |e verfasserin |4 aut | |
| 700 | 1 | |a Demirok, Ahmet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Retina (Philadelphia, Pa.) |d 1981 |g 35(2015), 10 vom: 01. Okt., Seite 2001-10 |w (DE-627)NLM012598550 |x 1539-2864 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2015 |g number:10 |g day:01 |g month:10 |g pages:2001-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/IAE.0000000000000605 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2015 |e 10 |b 01 |c 10 |h 2001-10 | ||